ファーマコビジランス市場の規模、シェア、予測、動向分析：オファリング別、フェーズ別、治療領域別、エンドユーザー別-2031年までの世界の予測

ファーマコビジランス市場は、2024年から2031年までのCAGRが10.7%で、2031年には180億5,000万米ドルに達すると予測されます。

本レポートは、ファーマコビジランス市場シナリオの広範な2次調査と1次調査、詳細な分析を経て、主要産業の促進要因・抑制要因・課題・機会の分析から構成されています。ファーマコビジランス市場の成長は、主に薬毒性の発生率の上昇、厳しい規制の枠組み、製薬研究費の増加、新薬開発のニーズの高まり、医療機器の安全性への注目の高まりによってもたらされます。しかし、ファーマコビジランス・サービスのコストが高いため、中小企業での導入が制限され、この市場の成長を抑制しています。

さらに、技術的に高度なソフトウェアのイントロダクション、医薬品の副作用に関する意識の高まり、薬剤の組み合わせを必要とする治療アプローチ、ファーマコビジランスサービスのアウトソーシングの増加は、この市場の利害関係者に成長機会をもたらすと予想されます。しかし、データ・セキュリティ・リスクと熟練したファーマコビジランス専門家の不足は、市場成長にとって大きな課題となっています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

• 概要
• 促進要因
  • 薬物毒性の発生率の上昇
  • 厳しい規制の枠組み
  • 医薬品研究費の増加
  • 新薬開発ニーズの高まり
  • 医療機器の安全性への関心の高まり
• 抑制要因
  • ファーマコビジランスサービスのコスト高
• 機会
  • 技術的に高度なソフトウェアのイントロダクション
  • 副作用報告に関する意識の高まり
  • 薬剤の組み合わせを必要とする治療アプローチ
  • ファーマコビジランス業務のアウトソーシングの増加
• 課題
  • データセキュリティリスク
  • 熟練したファーマコビジランス専門家の不足
• 要因分析
• 動向
• 規制分析
• ポーターのファイブフォース分析

第5章 ファーマコビジランス市場：オファリング別評価

• 概要
• ソフトウェア
  • 展開モード別ソフトウェア
    • オンプレミス
    • クラウドベース
  • 機能別ソフトウェア
    • 問題追跡ソフトウェア
    • 有害事象報告ソフトウェア
    • 完全統合ソフトウェア
    • 医薬品安全性監査ソフトウェア
    • その他の機能
• サービス内容
  • サービスプロバイダー別サービス
    • インハウス
    • アウトソーシング契約
  • タイプ別サービス
    • 自発的レポーティング
    • ADR報告強化型
    • 自発的報告
    • コホートイベントモニタリング
    • EHRマイニング
    • その他のサービス
  • プロセス別サービス
    • コアサービス
    • コンサルティングサービス
  • プロセス流出別サービス
    • ケースデータ管理
      • ケースロギング
      • 症例データ分析
      • メディカルレビューとレポート
    • シグナル検出
      • 有害事象の記録
      • 有害事象分析
      • 有害事象レビューと報告
    • リスク管理システム
      • リスク評価システム
      • リスク軽減システム

第6章 ファーマコビジランス市場：医薬品開発フェーズ別評価

• 概要
• フェーズIV
• フェーズ III
• フェーズ II
• フェーズ I
• 前臨床試験

第7章 ファーマコビジランス市場：治療領域別評価

• がん領域
• 循環器/血管疾患
• 感染症
• 免疫学
• 神経学
• その他の治療分野

第8章 ファーマコビジランス市場：エンドユーザー別評価

• 概要
• 製薬・バイオテクノロジー企業
• 医療機器メーカー
• 政府機関
• その他のエンドユーザー

第9章 ファーマコビジランス市場：地域別評価

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ベルギー
  • オランダ
  • デンマーク
  • スウェーデン
  • その他欧州（RoE）
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • その他アジア太平洋地域（RoAPAC）
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ（RoLATAM）
• 中東・アフリカ

第10章 競合分析

• 概要
• 主要成長戦略
• 競合ベンチマーキング
• 競合ダッシュボード
  • 業界リーダー
  • 市場差別化要因
  • 先行企業
  • 新興企業
• 主要企業の市場シェア分析／市場ランキング（2023年）

第11章 企業プロファイル（企業概要、財務概要、製品ポートフォリオ、戦略的展開、*SWOT分析）

• IQVIA
• Cognizant Technology Solutions Corporation
• Linical Co., Ltd
• International Business Machines Corporation
• Laboratory Corporation of America Holdings
• ICON plc
• Parexel International
• Wipro Limited
• Sanofi S.A.
• Pharmaceutical Product Development, Inc.（A Subsidiary of Thermo Fisher Scientific Inc.）
• Capgemini SE
• Syneos Health
• ArisGlobal
• Ennov
• EXTEDO GmbH
• Oracle Corporation
• Sparta Systems Inc
• United BioSource, LLC（UBC）
• AB Cube S.A.S.

（注：SWOT分析は上位5社について提供される）

第12章 付録

LIST OF TABLES

• Table 1 Global Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 2 Global Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 3 Global Pharmacovigilance Software Market, by Country/Region, 2022-2031 (USD Million)
• Table 4 Global On-premise Pharmacovigilance Software Market, by Country/Region, 2022-2031 (USD Million)
• Table 5 Global Cloud-based Pharmacovigilance Software Market, by Country/Region, 2022-2031 (USD Million)
• Table 6 Global Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 7 Global Pharmacovigilance Issue Tracking Software Market, by Country/Region, 2022-2031 (USD Million)
• Table 8 Global Pharmacovigilance Adverse Event Reporting Software Market, by Country/Region, 2022-2031 (USD Million)
• Table 9 Global Pharmacovigilance Fully Integrated Software Market, by Country/Region, 2022-2031 (USD Million)
• Table 10 Global Pharmacovigilance Drug Safety Audit Software Market, by Country/Region, 2022-2031 (USD Million)
• Table 11 Global Pharmacovigilance Software Market for Other Functionalities, by Country/Region, 2022-2031 (USD Million)
• Table 12 Global Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 13 Global Pharmacovigilance Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 14 Global In-house Pharmacovigilance Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 15 Global Contract Outsourcing Pharmacovigilance Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 16 Global Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 17 Global Pharmacovigilance Spontaneous Reporting Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 18 Global Pharmacovigilance Intensified ADR Reporting Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 19 Global Pharmacovigilance Targeted Spontaneous Reporting Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 20 Global Pharmacovigilance Cohort Event Monitoring Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 21 Global Pharmacovigilance EHR Mining Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 22 Global Other Pharmacovigilance Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 23 Global Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 24 Global Pharmacovigilance Core Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 25 Global Pharmacovigilance Consulting Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 26 Global Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 27 Global Pharmacovigilance Case Data Management Services Market, by Type, 2022-2031 (USD Million)
• Table 28 Global Pharmacovigilance Case Data Management Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 29 Global Pharmacovigilance Case Logging Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 30 Global Pharmacovigilance Case Data Analysis Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 31 Global Pharmacovigilance Medical Review & Reporting Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 32 Global Pharmacovigilance Signal Detection Services Market, by Type, 2022-2031 (USD Million)
• Table 33 Global Pharmacovigilance Signal Detection Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 34 Global Pharmacovigilance Adverse Event Logging Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 35 Global Pharmacovigilance Adverse Event Analysis Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 36 Global Pharmacovigilance Adverse Event Review & Reporting Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 37 Global Pharmacovigilance Risk Management System Services Market, by Type, 2022-2031 (USD Million)
• Table 38 Global Pharmacovigilance Risk Management System Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 39 Global Pharmacovigilance Risk Evaluation System Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 40 Global Pharmacovigilance Risk Mitigation System Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 41 Global Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 42 Global Pharmacovigilance Market for Phase IV, by Country/Region, 2022-2031 (USD Million)
• Table 43 Global Pharmacovigilance Market for Phase III, by Country/Region, 2022-2031 (USD Million)
• Table 44 Global Pharmacovigilance Market for Phase II, by Country/Region, 2022-2031 (USD Million)
• Table 45 Global Pharmacovigilance Market for Phase I, by Country/Region, 2022-2031 (USD Million)
• Table 46 Global Pharmacovigilance Market for Preclinical Studies, by Country/Region, 2022-2031 (USD Million)
• Table 47 Global Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 48 Global Pharmacovigilance Market for Oncology, by Country/Region, 2022-2031 (USD Million)
• Table 49 Global Pharmacovigilance Market for Cardiology/Vascular Diseases, by Country/Region, 2022-2031 (USD Million)
• Table 50 Global Pharmacovigilance Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
• Table 51 Global Pharmacovigilance Market for Immunology, by Country/Region, 2022-2031 (USD Million)
• Table 52 Global Pharmacovigilance Market for Neurology, by Country/Region, 2022-2031 (USD Million)
• Table 53 Global Pharmacovigilance Market for Other Therapeutic Areas, by Country/Region, 2022-2031 (USD Million)
• Table 54 Global Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 55 Global Pharmacovigilance Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
• Table 56 Global Pharmacovigilance Market for Medical Device Manufacturers, by Country/Region, 2022-2031 (USD Million)
• Table 57 Global Pharmacovigilance Market for Government Agencies, by Country/Region, 2022-2031 (USD Million)
• Table 58 Global Pharmacovigilance Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
• Table 59 Global Pharmacovigilance Market, by Country/Region, 2022-2031 (USD Million)
• Table 60 North America: Pharmacovigilance Market, by Country, 2022-2031 (USD Million)
• Table 61 North America: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 62 North America: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 63 North America: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 64 North America: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 65 North America: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 66 North America: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 67 North America: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 68 North America: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 69 North America: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 70 North America: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 71 U.S.: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 72 U.S.: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 73 U.S.: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 74 U.S.: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 75 U.S.: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 76 U.S.: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 77 U.S.: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 78 U.S.: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 79 U.S.: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 80 U.S.: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 81 Canada: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 82 Canada: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 83 Canada: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 84 Canada: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 85 Canada: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 86 Canada: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 87 Canada: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 88 Canada: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 89 Canada: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 90 Canada: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 91 Europe: Pharmacovigilance Market, by Country/Region, 2022-2031 (USD Million)
• Table 92 Europe: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 93 Europe: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 94 Europe: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 95 Europe: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 96 Europe: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 97 Europe: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 98 Europe: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 99 Europe: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 100 Europe: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 101 Europe: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 102 Germany: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 103 Germany: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 104 Germany: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 105 Germany: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 106 Germany: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 107 Germany: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 108 Germany: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 109 Germany: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 110 Germany: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 111 Germany: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 112 France: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 113 France: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 114 France: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 115 France: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 116 France: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 117 France: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 118 France: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 119 France: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 120 France: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 121 France: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 122 U.K.: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 123 U.K.: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 124 U.K.: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 125 U.K.: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 126 U.K.: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 127 U.K.: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 128 U.K.: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 129 U.K.: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 130 U.K.: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 131 U.K.: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 132 Italy: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 133 Italy: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 134 Italy: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 135 Italy: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 136 Italy: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 137 Italy: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 138 Italy: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 139 Italy: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 140 Italy: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 141 Italy: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 142 Spain: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 143 Spain: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 144 Spain: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 145 Spain: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 146 Spain: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 147 Spain: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 148 Spain: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 149 Spain: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 150 Spain: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 151 Spain: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 152 Belgium: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 153 Belgium: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 154 Belgium: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 155 Belgium: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 156 Belgium: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 157 Belgium: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 158 Belgium: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 159 Belgium: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 160 Belgium: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 161 Belgium: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 162 Netherlands: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 163 Netherlands: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 164 Netherlands: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 165 Netherlands: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 166 Netherlands: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 167 Netherlands: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 168 Netherlands: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 169 Netherlands: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 170 Netherlands: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 171 Netherlands: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 172 Denmark: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 173 Denmark: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 174 Denmark: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 175 Denmark: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 176 Denmark: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 177 Denmark: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 178 Denmark: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 179 Denmark: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 180 Denmark: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 181 Denmark: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 182 Sweden: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 183 Sweden: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 184 Sweden: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 185 Sweden: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 186 Sweden: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 187 Sweden: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 188 Sweden: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 189 Sweden: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 190 Sweden: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 191 Sweden: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 192 Rest of Europe: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 193 Rest of Europe: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 194 Rest of Europe: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 195 Rest of Europe: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 196 Rest of Europe: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 197 Rest of Europe: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 198 Rest of Europe: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 199 Rest of Europe: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 200 Rest of Europe: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 201 Rest of Europe: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 202 Asia-Pacific: Pharmacovigilance Market, by Country/Region, 2022-2031 (USD Million)
• Table 203 Asia-Pacific: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 204 Asia-Pacific: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 205 Asia-Pacific: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 206 Asia-Pacific: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 207 Asia-Pacific: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 208 Asia-Pacific: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 209 Asia-Pacific: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 210 Asia-Pacific: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 211 Asia-Pacific: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 212 Asia-Pacific: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 213 China: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 214 China: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 215 China: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 216 China: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 217 China: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 218 China: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 219 China: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 220 China: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 221 China: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 222 China: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 223 Japan: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 224 Japan: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 225 Japan: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 226 Japan: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 227 Japan: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 228 Japan: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 229 Japan: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 230 Japan: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 231 Japan: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 232 Japan: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 233 India: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 234 India: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 235 India: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 236 India: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 237 India: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 238 India: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 239 India: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 240 India: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 241 India: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 242 India: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 243 South Korea: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 244 South Korea: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 245 South Korea: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 246 South Korea: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 247 South Korea: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 248 South Korea: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 249 South Korea: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 250 South Korea: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 251 South Korea: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 252 South Korea: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 253 Australia: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 254 Australia: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 255 Australia: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 256 Australia: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 257 Australia: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 258 Australia: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 259 Australia: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 260 Australia: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 261 Australia: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 262 Australia: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 263 Rest of Asia-Pacific: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 264 Rest of Asia-Pacific: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 265 Rest of Asia-Pacific: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 266 Rest of Asia-Pacific: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 267 Rest of Asia-Pacific: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 268 Rest of Asia-Pacific: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 269 Rest of Asia-Pacific: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 270 Rest of Asia-Pacific: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 271 Rest of Asia-Pacific: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 272 Rest of Asia-Pacific: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 273 Latin America: Pharmacovigilance Market, by Country/Region, 2022-2031 (USD Million)
• Table 274 Latin America: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 275 Latin America: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 276 Latin America: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 277 Latin America: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 278 Latin America: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 279 Latin America: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 280 Latin America: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 281 Latin America: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 282 Latin America: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 283 Latin America: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 284 Brazil: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 285 Brazil: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 286 Brazil: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 287 Brazil: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 288 Brazil: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 289 Brazil: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 290 Brazil: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 291 Brazil: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 292 Brazil: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 293 Brazil: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 294 Mexico: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 295 Mexico: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 296 Mexico: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 297 Mexico: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 298 Mexico: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 299 Mexico: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 300 Mexico: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 301 Mexico: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 302 Mexico: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 303 Mexico: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 304 Rest of Latin America: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 305 Rest of Latin America: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 306 Rest of Latin America: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 307 Rest of Latin America: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 308 Rest of Latin America: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 309 Rest of Latin America: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 310 Rest of Latin America: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 311 Rest of Latin America: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 312 Rest of Latin America: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 313 Rest of Latin America: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 314 Middle East & Africa: Pharmacovigilance Market, by Offering, 2022-2031 (USD Million)
• Table 315 Middle East & Africa: Pharmacovigilance Software Market, by Deployment Mode, 2022-2031 (USD Million)
• Table 316 Middle East & Africa: Pharmacovigilance Software Market, by Functionality, 2022-2031 (USD Million)
• Table 317 Middle East & Africa: Pharmacovigilance Services Market, by Service Provider, 2022-2031 (USD Million)
• Table 318 Middle East & Africa: Pharmacovigilance Services Market, by Type, 2022-2031 (USD Million)
• Table 319 Middle East & Africa: Pharmacovigilance Services Market, by Process, 2022-2031 (USD Million)
• Table 320 Middle East & Africa: Pharmacovigilance Services Market, by Process Outflow, 2022-2031 (USD Million)
• Table 321 Middle East & Africa: Pharmacovigilance Market, by Drug Development Phase, 2022-2031 (USD Million)
• Table 322 Middle East & Africa: Pharmacovigilance Market, by Therapeutic Area, 2022-2031 (USD Million)
• Table 323 Middle East & Africa: Pharmacovigilance Market, by End User, 2022-2031 (USD Million)
• Table 324 Recent Developments, by Company, 2020-2024

LIST OF FIGURES

• Figure 1 Research Process
• Figure 2 Key Secondary Sources
• Figure 3 Primary Research Techniques
• Figure 4 Key Executives Interviewed
• Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
• Figure 6 Market Size Estimation
• Figure 7 Global Pharmacovigilance Market, by Offering, 2024 Vs. 2031 (USD Million)
• Figure 8 Global Pharmacovigilance Market, by Drug Development Phase, 2024 Vs. 2031 (USD Million)
• Figure 9 Global Pharmacovigilance Market, by Therapeutic Area, 2024 Vs. 2031 (USD Million)
• Figure 10 Global Pharmacovigilance Market, by End User, 2024 Vs. 2031 (USD Million)
• Figure 11 Global Pharmacovigilance Market, by Geography
• Figure 12 Global Pharmacovigilance Market, by Offering, 2024 Vs. 2031 (USD Million)
• Figure 13 Global Pharmacovigilance Market, by Drug Development Phase, 2024 Vs. 2031 (USD Million)
• Figure 14 Global Pharmacovigilance Market, by Therapeutic Area, 2024 Vs. 2031 (USD Million)
• Figure 15 Global Pharmacovigilance Market, by End User, 2024 Vs. 2031 (USD Million)
• Figure 16 Global Pharmacovigilance Market, by Geography, 2024 Vs. 2031 (USD Million)
• Figure 17 North America: Pharmacovigilance Market Snapshot
• Figure 18 Europe: Pharmacovigilance Market Snapshot
• Figure 19 Asia-Pacific: Pharmacovigilance Market Snapshot
• Figure 20 Latin America: Pharmacovigilance Market Snapshot
• Figure 21 Key Growth Strategies Adopted by Leading Players, 2020-2024
• Figure 22 Global Pharmacovigilance Market: Competitive Benchmarking, by Offering
• Figure 23 Global Pharmacovigilance Market: Competitive Benchmarking, by Geography
• Figure 24 Global Pharmacovigilance Market: Competitive Dashboard
• Figure 25 Global Pharmacovigilance Market: Market Share Analysis/Market Rankings (2023)
• Figure 26 IQVIA: Financial Snapshot (2023)
• Figure 27 Cognizant Technology Solutions Corporation: Financial Snapshot (2023)
• Figure 28 Linical Co., Ltd.: Financial Snapshot (2023)
• Figure 29 International Business Machines Corporation: Financial Snapshot (2023)
• Figure 30 Laboratory Corporation of America Holdings: Financial Snapshot (2023)
• Figure 31 ICON plc: Financial Snapshot (2023)
• Figure 32 Wipro Limited: Financial Snapshot (2023)
• Figure 33 Sanofi S.A.: Financial Snapshot (2023)
• Figure 34 Pharmaceutical Product Development Inc.: Financial Snapshot (2023)
• Figure 35 Capgemini SE: Financial Snapshot (2023)
• Figure 36 Syneos Health: Financial Snapshot (2023)
• Figure 37 Oracle Corporation: Financial Snapshot (2023)

Pharmacovigilance Market Size, Share, Forecast, & Trends Analysis by Offering (Software [Adverse Event Reporting, Issue Tracking, Drug Safety Audit], Services [Spontaneous Reporting, Case Logging]), Phase, Therapeutic Area, End User-Global Forecast to 2031

The pharmacovigilance market is projected to reach $18.05 billion by 2031 at a CAGR of 10.7% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the pharmacovigilance market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the pharmacovigilance market is mainly driven by the rising incidence of drug toxicity, stringent regulatory frameworks, increasing pharmaceutical research spending, rising need for new drug development, and the increasing focus on medical device safety. However, the high costs of pharmacovigilance services limit their adoption among small & mid-sized companies, restraining the growth of this market.

Furthermore, the introduction of technologically advanced software, growing awareness regarding adverse drug reactions, therapeutic approaches requiring a combination of drugs, and the increasing outsourcing of pharmacovigilance services are expected to generate growth opportunities for the stakeholders in this market. However, data security risks and the shortage of skilled pharmacovigilance professionals pose major challenges for market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the pharmacovigilance market are IQVIA (U.S.), Cognizant Technology Solutions Corporation (U.S.), Linical Co., Ltd (U.S.), International Business Machines Corporation (U.S.), Laboratory Corporation of America Holdings (U.S.), ICON plc (Ireland), Parexel International (U.S.), Wipro Limited (India), Sanofi S.A. (France), Pharmaceutical Product Development Inc. (a subsidiary of Thermo Fisher Scientific Inc.) (U.S.), Capgemini SE (France), Syneos Health (U.S.), ArisGlobal (U.S.), Ennov (France), EXTEDO GmbH (Germany), Oracle Corporation (U.S.), Sparta Systems Inc. (U.S.), United BioSource, LLC (UBC) (U.S.), and AB Cube S.A.S. (France).

Based on offering, in 2024, the services segment is expected to account for the largest share of over 97.6% of the pharmacovigilance market. The services segment is further segmented into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, EHR mining, and other services based on type. The increasing number of molecules in clinical development and the growing importance of drug safety are driving the outsourcing of pharmacovigilance services. Additionally, the need for regulatory compliance, rising drug complexity, globalization of clinical trials, and increasing awareness about drug safety are further contributing to the segment's growth.

Based on drug development phase, the Phase IV segment is projected to witness the highest growth rate during the forecast period 2024-2031. The study design and sample sizes are larger and more complex in Phase IV as the drug is tested post-approval; hence, the demand for pharmacovigilance services is higher in Phase IV due to the need for efficient management and data analysis. Additionally, the high complexity of Phase IV is increasing the adoption of pharmacovigilance services for the efficient management of clinical trials.

Based on therapeutic area, in 2024, the oncology segment is expected to account for the largest share of the pharmacovigilance market. According to GLOBOCAN, the prevalence of cancer is expected to reach 32.64 million in 2045 from 19.98 million in 2022. The rising prevalence of cancer is increasing the demand for newer therapies and drugs, driving the adoption of pharmacovigilance software and services. Additionally, the availability of funding for oncology, life sciences & healthcare research, the increasing demand for personalized therapies, and the high cancer incidence necessitating newer therapies to be launched in the market are contributing to segment growth.

Based on end user, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the pharmacovigilance market. The large market share of this segment is attributed to the increasing R&D investments by pharmaceutical & biotechnology companies and rising funding for pharmaceutical research. Additionally, changing regulations across the pharmaceutical industry are increasing the adoption of pharmacovigilance tools to support regulatory submissions for drug approval, timely & accurate reporting of ADRs, and ensuring compliance with changing regulatory requirements.

An in-depth analysis of the geographical scenario of the global pharmacovigilance market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.

In 2024, North America is expected to account for the largest share of over 44.3% of the pharmacovigilance market. The large share of the regional market is attributed to the presence of key players, advanced infrastructure and resources supporting research & development, the large number of clinical trials and drug approvals, and increased reporting of adverse drug events in the region.

Scope of the Report:

Pharmacovigilance Market Assessment-by Offering

• Software
  • Software, by Deployment Mode
• On-premise
• Cloud-based
  • Software, by Functionality
• Issue Tracking Software
• Adverse Event Reporting Software
• Fully Integrated Software
• Drug Safety Audit Software
• Other Functionalities
• Services
  • Services, by Service Provider
• In-house
• Contract Outsourcing
  • Services, by Type
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining
• Other Services
  • Services, by Process
• Core Services
• Consulting Services
  • Services, by Process Outflow
• Case Data Management
• Case Logging
• Case Data Analysis
• Medical Review & Reporting
• Signal Detection
• Adverse Event Logging
• Adverse Event Analysis
• Adverse Event Review & Reporting
• Risk Management System
• Risk Evaluation System
• Risk Mitigation System

Note: Other Functionalities comprise reporting and analytics, case management, and signal management.

Note: Other Services comprise case processing, signal management, regulatory intelligence, and consulting services.

Pharmacovigilance Market Assessment-by Drug Development Phase

• Phase IV
• Phase III
• Phase II
• Phase I
• Preclinical Studies

Pharmacovigilance Market Assessment-by Therapeutic Area

• Oncology
• Cardiology/Vascular Diseases
• Infectious Diseases
• Immunology
• Neurology
• Other Therapeutic Areas

Pharmacovigilance Market Assessment-by End User

• Pharmaceutical & Biotechnology Companies
• Medical Device Manufacturers
• Government Agencies
• Other End Users

Note: Other End Users comprise CROs and BPOs.

Pharmacovigilance Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Belgium
  • Netherlands
  • Sweden
  • Denmark
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Data Collection & Validation Process
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
• 2.3. Market Sizing & Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Rising Incidence of Drug Toxicity
  • 4.2.2. Stringent Regulatory Frameworks
  • 4.2.3. Increasing Pharmaceutical Research Spending
  • 4.2.4. Rising Need for the Development of New Drugs
  • 4.2.5. Growing Focus on Medical Device Safety
• 4.3. Restraints
  • 4.3.1. High Costs of Pharmacovigilance Services
• 4.4. Opportunities
  • 4.4.1. Introduction of Technologically Advanced Software
  • 4.4.2 Growing Awareness Regarding the Reporting of Adverse Drug Reactions
  • 4.4.3. Therapeutic Approaches Requiring Drug Combinations
  • 4.4.4. Increasing Outsourcing of Pharmacovigilance Services
• 4.5. Challenges
  • 4.5.1. Data Security Risks
  • 4.5.2. Shortage of Skilled Pharmacovigilance Professionals
• 4.6. Factor Analysis
• 4.7. Trends
• 4.8. Regulatory Analysis
• 4.9. Porter's Five Force Analysis

5. Pharmacovigilance Market Assessment-by Offering

• 5.1. Overview
• 5.2. Software
  • 5.2.1. Software, by Deployment Mode
    • 5.2.1.1. On-premise
    • 5.2.1.2. Cloud-based
  • 5.2.2. Software, by Functionality
    • 5.2.2.1. Issue Tracking Software
    • 5.2.2.2. Adverse Event Reporting Software
    • 5.2.2.3. Fully Integrated Software
    • 5.2.2.4. Drug Safety Audit Software
    • 5.2.2.5. Other Functionalities
• 5.3. Services
  • 5.3.1. Services, by Service Provider
    • 5.3.1.1. In-house
    • 5.3.1.2. Contract Outsourcing
  • 5.3.2. Services, by Type
    • 5.3.2.1. Spontaneous Reporting
    • 5.3.2.2. Intensified ADR Reporting
    • 5.3.2.3. Targeted Spontaneous Reporting
    • 5.3.2.4. Cohort Event Monitoring
    • 5.3.2.5. EHR Mining
    • 5.3.2.6. Other Services
  • 5.3.3. Services, by process
    • 5.3.3.1. Core Services
    • 5.3.3.2. Consulting Services
  • 5.3.4. Services, by Process Outflow
    • 5.3.4.1. Case Data Management
      • 5.3.4.1.1. Case Logging
      • 5.3.4.1.2. Case Data Analysis
      • 5.3.4.1.3. Medical Review & Reporting
    • 5.3.4.2. Signal Detection
      • 5.3.4.2.1. Adverse Event Logging
      • 5.3.4.2.2. Adverse Event Analysis
      • 5.3.4.2.3. Adverse Event Review & Reporting
    • 5.3.4.3. Risk Management Systems
      • 5.3.4.3.1. Risk Evaluation Systems
      • 5.3.4.3.2. Risk Mitigation Systems

6. Pharmacovigilance Market Assessment-by Drug Development Phase

• 6.1. Overview
• 6.2. Phase IV
• 6.3. Phase III
• 6.4. Phase II
• 6.5. Phase I
• 6.6. Preclinical Studies

7. Pharmacovigilance Market Assessment-by Therapeutic Area

• 7.1. Oncology
• 7.2. Cardiology/Vascular Diseases
• 7.3. Infectious Diseases
• 7.4. Immunology
• 7.5. Neurology
• 7.6. Other Therapeutic Areas

8. Pharmacovigilance Market Assessment-by End User

• 8.1. Overview
• 8.2. Pharmaceutical & Biotechnology Companies
• 8.3. Medical Device Manufacturers
• 8.4. Government Agencies
• 8.5. Other End Users

9. Pharmacovigilance Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Belgium
  • 9.3.7. Netherlands
  • 9.3.8. Denmark
  • 9.3.9. Sweden
  • 9.3.10. Rest of Europe (RoE)
• 9.4. Asia-Pacific
  • 9.4.1. Japan
  • 9.4.2. China
  • 9.4.3. India
  • 9.4.4. South Korea
  • 9.4.5. Australia
  • 9.4.6. Rest of Asia-Pacific (RoAPAC)
• 9.5. Latin America
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America (RoLATAM)
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Share Analysis/Market Rankings of Key Players (2023)

11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and *SWOT Analysis)

• 11.1. IQVIA
• 11.2. Cognizant Technology Solutions Corporation
• 11.3. Linical Co., Ltd
• 11.4. International Business Machines Corporation
• 11.5. Laboratory Corporation of America Holdings
• 11.6. ICON plc
• 11.7. Parexel International
• 11.8. Wipro Limited
• 11.9. Sanofi S.A.
• 11.10 Pharmaceutical Product Development, Inc. (A Subsidiary of Thermo Fisher Scientific Inc.)
• 11.11. Capgemini SE
• 11.12. Syneos Health
• 11.13. ArisGlobal
• 11.14. Ennov
• 11.15. EXTEDO GmbH
• 11.16. Oracle Corporation
• 11.17. Sparta Systems Inc
• 11.18. United BioSource, LLC (UBC)
• 11.19. AB Cube S.A.S.

(Note: SWOT analysis will be provided for the top 5 companies.)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports